$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

$alny Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-K Financial Statement

#000119312513065475 Filed on February 19, 2013

Income Statement

Concept	2013 Q1	2012 Q4	2011 Q4
Revenue	$18.60M	$8.500M	$20.50M
YoY Change	-9.71%	-58.54%	-3.3%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$6.300M	$10.20M	$10.70M
YoY Change	-39.42%	-4.67%	42.67%
% of Gross Profit
Research & Development	$22.18M	$21.70M	$23.40M
YoY Change	5.24%	-7.26%	-10.34%
% of Gross Profit
Depreciation & Amortization	$2.127M	$2.000M	$1.200M
YoY Change	0.28%	66.67%	0.0%
% of Gross Profit
Operating Expenses	$28.45M	$96.84M	$34.04M
YoY Change	-9.64%	184.49%	1.31%
Operating Profit	-$9.804M
YoY Change	-10.0%
Interest Expense	$200.0K	-$700.0K	-$700.0K
YoY Change	-128.57%	0.0%	75.0%
% of Operating Profit
Other Income/Expense, Net	$229.0K	$16.20M	-$2.300M
YoY Change	-148.21%	-804.35%	-135.94%
Pretax Income	-$9.575M	-$72.80M	-$16.60M
YoY Change	-15.77%	338.55%	155.38%
Income Tax	-$562.0K	-$10.60M	$0.00
% Of Pretax Income
Net Earnings	-$9.013M	-$62.19M	-$14.30M
YoY Change	-20.72%	334.79%	107.29%
Net Earnings / Revenue	-48.46%	-731.62%	-69.77%
Basic Earnings Per Share
Diluted Earnings Per Share	-$152.0K	-$1.194M	-$388.8K
COMMON SHARES
Basic Shares Outstanding	61.87M shares	52.41M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2013 Q1	2012 Q4	2011 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$236.0M	$122.8M	$146.4M
YoY Change	18.54%	-16.11%	-37.19%
Cash & Equivalents	$97.80M	$51.41M	$70.23M
Short-Term Investments	$138.2M	$71.41M	$76.17M
Other Short-Term Assets	$3.500M	$2.600M	$4.200M
YoY Change	-52.05%	-38.1%	-39.13%
Inventory
Prepaid Expenses
Receivables	$600.0K	$100.0K	$1.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$240.1M	$125.6M	$152.0M
YoY Change	15.16%	-17.41%	-40.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.98M	$19.80M	$14.64M
YoY Change	38.56%	35.21%	-19.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$212.5M	$142.2M	$114.4M
YoY Change	80.39%	24.3%	-4.98%
Other Assets		$101.0K	$839.0K
YoY Change		-87.96%
Total Long-Term Assets	$231.5M	$162.0M	$129.9M
YoY Change	75.62%	24.69%	-6.69%
TOTAL ASSETS
Total Short-Term Assets	$240.1M	$125.6M	$152.0M
Total Long-Term Assets	$231.5M	$162.0M	$129.9M
Total Assets	$471.6M	$287.5M	$281.9M
YoY Change	38.58%	1.99%	-28.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.105M	$4.420M	$5.800M
YoY Change	-27.79%	-23.79%	-37.63%
Accrued Expenses	$9.086M	$11.56M	$12.34M
YoY Change	-30.11%	-6.34%	11.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$49.75M	$48.35M	$80.99M
YoY Change	-25.3%	-40.31%	-20.6%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$110.3M	$105.1M	$716.0K
YoY Change	44.56%	14578.77%	-99.46%
Total Long-Term Liabilities	$110.3M	$105.1M	$716.0K
YoY Change	44.56%	14578.77%	-99.46%
TOTAL LIABILITIES
Total Short-Term Liabilities	$49.75M	$48.35M	$80.99M
Total Long-Term Liabilities	$110.3M	$105.1M	$716.0K
Total Liabilities	$160.0M	$153.5M	$163.9M
YoY Change	11.98%	-6.38%	-30.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$516.0M	-$507.0M	-$401.0M
YoY Change		26.44%
Common Stock	$806.8M	$625.4M	$519.2M
YoY Change		20.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$311.6M	$134.1M	$118.0M
YoY Change
Total Liabilities & Shareholders Equity	$471.6M	$287.5M	$281.9M
YoY Change	38.58%	1.99%	-28.32%

Cashflow Statement

Concept	2013 Q1	2012 Q4	2011 Q4
OPERATING ACTIVITIES
Net Income	-$9.013M	-$62.19M	-$14.30M
YoY Change	-20.72%	334.79%	107.29%
Depreciation, Depletion And Amortization	$2.127M	$2.000M	$1.200M
YoY Change	0.28%	66.67%	0.0%
Cash From Operating Activities	-$971.0K	-$68.90M	-$25.20M
YoY Change	-96.79%	173.41%	24.14%
INVESTING ACTIVITIES
Capital Expenditures	$1.799M	-$600.0K	-$500.0K
YoY Change	584.03%	20.0%	-54.55%
Acquisitions
YoY Change
Other Investing Activities	-$129.0M	$44.20M	$21.40M
YoY Change	97.55%	106.54%	-56.06%
Cash From Investing Activities	-$130.8M	$43.50M	$20.80M
YoY Change	99.47%	109.13%	-56.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$173.6M
YoY Change	100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	178.2M	1.000M	200.0K
YoY Change	104.09%	400.0%	-66.67%
NET CHANGE
Cash From Operating Activities	-971.0K	-68.90M	-25.20M
Cash From Investing Activities	-130.8M	43.50M	20.80M
Cash From Financing Activities	178.2M	1.000M	200.0K
Net Change In Cash	46.40M	-24.40M	-4.200M
YoY Change	-646.58%	480.95%	-115.11%
FREE CASH FLOW
Cash From Operating Activities	-$971.0K	-$68.90M	-$25.20M
Capital Expenditures	$1.799M	-$600.0K	-$500.0K
Free Cash Flow	-$2.770M	-$68.30M	-$24.70M
YoY Change	-90.91%	176.52%	28.65%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61866821	shares
CY2009Q1	alny	Preferred Stock Purchased PreferredStockPurchased	10000000
CY2012Q1	us-gaap	Share Price SharePrice	10.75
CY2012Q2	dei	Entity Public Float EntityPublicFloat	532319660
CY2012Q3	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.44	pure
CY2009Q4	us-gaap	Stockholders Equity StockholdersEquity	177965000
CY2009Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	137468000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4983088	shares
CY2010Q4	us-gaap	Stockholders Equity StockholdersEquity	158233000
CY2010Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.60
CY2010Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	428000
CY2010Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	74599000
CY2011Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4158000
CY2011Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	114407000
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	6065000
CY2011Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	45566000
CY2011Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	518731000
CY2011Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	154423000
CY2011Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-91000
CY2011Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	839000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6033858	shares
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	12405000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	117997000
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	5192000
CY2011Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	190746000
CY2011Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2011Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	53485000
CY2011Q4	us-gaap	Equity Method Investment Summarized Financial Information Current Liabilities EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities	12850000
CY2011Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	3196000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.13
CY2011Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42721942	shares
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	6550000
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	6303000
CY2011Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1468000
CY2011Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	91000
CY2011Q4	us-gaap	Liabilities Liabilities	163920000
CY2011Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5800000
CY2011Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	128000
CY2011Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	46230000
CY2011Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	62366000
CY2011Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2850000
CY2011Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	5338000
CY2011Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	716000
CY2011Q4	us-gaap	Equity Method Investment Summarized Financial Information Current Assets EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets	38666000
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	364000
CY2011Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2011Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-400996000
CY2011Q4	us-gaap	Assets Assets	281917000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.53
CY2011Q4	us-gaap	Equity Method Investment Summarized Financial Information Assets EquityMethodInvestmentSummarizedFinancialInformationAssets	42881000
CY2011Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	78000
CY2011Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	21855000
CY2011Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	281917000
CY2011Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	19676000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70228000
CY2011Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	243000
CY2011Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42721942	shares
CY2011Q4	us-gaap	Equity Method Investment Summarized Financial Information Noncurrent Liabilities EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities	28834000
CY2011Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-165000
CY2011Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12340000
CY2011Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1784000
CY2011Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	484000
CY2011Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	76174000
CY2011Q4	us-gaap	Liabilities Current LiabilitiesCurrent	80990000
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9778539	shares
CY2011Q4	us-gaap	Common Stock Value CommonStockValue	427000
CY2011Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	3727000
CY2011Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2011Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	78487000
CY2011Q4	us-gaap	Assets Current AssetsCurrent	152028000
CY2011Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2011Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	154423000
CY2011Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2011Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2011Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	24474000
CY2011Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30923000
CY2011Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14643000
CY2011Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4302000
CY2011Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	788000
CY2011Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	190581000
CY2011Q4	alny	Equity Method Investment Summarized Financial Information Cash Cash Equivalents And Marketable Securities EquityMethodInvestmentSummarizedFinancialInformationCashCashEquivalentsAndMarketableSecurities	38144000
CY2011Q4	alny	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	3974000
CY2011Q4	alny	Equity Method Investments Summarized Financial Information Notes Payable EquityMethodInvestmentsSummarizedFinancialInformationNotesPayable	11259000
CY2011Q4	alny	Equity Method Investment Summarized Financial Information Net Assets EquityMethodInvestmentSummarizedFinancialInformationNetAssets	1197000
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2540000
CY2012Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	103416000
CY2012Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	55268000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	815916	shares
CY2012Q4	us-gaap	Net Rentable Area NetRentableArea	129000	sqft
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	624876000
CY2012Q4	us-gaap	Purchase Obligation PurchaseObligation	11100000
CY2012Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	192721000
CY2012Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	-38000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	101000
CY2012Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	14700000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5885363	shares
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	17443000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	134053000
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	174889000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	8209000
CY2012Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	24900000
CY2012Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	30776000
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Foreign DeferredTaxAssetsTaxCreditCarryforwardsForeign	3196000
CY2012Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	1563000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	17.20
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	41800000
CY2012Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	793000
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	52489936	shares
CY2012Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	818000
CY2012Q4	us-gaap	Available For Sale Securities Equity Securities AvailableForSaleSecuritiesEquitySecurities	38748000
CY2012Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	104000
CY2012Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	38000
CY2012Q4	us-gaap	Liabilities Liabilities	153467000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4420000
CY2012Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	102819000
CY2012Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	773000
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	31417000
CY2012Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4173000
CY2012Q4	us-gaap	Deferred Tax Assets Equity Method Investments DeferredTaxAssetsEquityMethodInvestments	7118000
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-507010000
CY2012Q4	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	10000000
CY2012Q4	us-gaap	Assets Assets	287520000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.71
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	24804000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	12.82
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	31000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	287520000
CY2012Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	19862000
CY2012Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	10300000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51405000
CY2012Q4	us-gaap	Available For Sale Securities Gross Unrealized Losses1 AvailableForSaleSecuritiesGrossUnrealizedLosses1	97000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52489936	shares
CY2012Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	10572000
CY2012Q4	us-gaap	Deferred Tax Liabilities Investments DeferredTaxLiabilitiesInvestments	6466000
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15662000
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11558000
CY2012Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	1793000
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	950000
CY2012Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	71407000
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48345000
CY2012Q4	us-gaap	Contractual Obligation ContractualObligation	27569000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8931583	shares
CY2012Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	9159000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	525000
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	4248000
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	100874000
CY2012Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	14463000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	125456000
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2012Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	209759000
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	35469000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19799000
CY2012Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2540000
CY2012Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	788000
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	174823000
CY2012Q4	alny	Number Of Operating Entities NumberOfOperatingEntities	4	Entity
CY2012Q4	alny	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageExercisePrice	5.56
CY2012Q4	alny	Share Based Compensation Arrangement By Share Based Payment Award Options Vesting Percentage In Each Quarter ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingPercentageInEachQuarter	0.0625	pure
CY2012Q4	alny	Deferred Tax Assets Capitalized Research And Development Costs DeferredTaxAssetsCapitalizedResearchAndDevelopmentCosts	16102000
CY2012Q4	alny	Purchase Obligation Thereafter PurchaseObligationThereafter	800000
CY2012Q4	alny	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	14700000
CY2012Q4	alny	Carrying Value In Equity Securities CarryingValueInEquitySecurities	12400000
CY2012Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	86800000
CY2010	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	106384000
CY2010	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3663000
CY2012Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	5900000
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8625000	shares
CY2012Q1	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.33	pure
CY2012Q1	alny	Restructuring And Related Cost Expected Number Of Employees Remaining RestructuringAndRelatedCostExpectedNumberOfEmployeesRemaining	115	Employee
CY2010	us-gaap	Share Based Goods And Nonemployee Services Transaction Expense ShareBasedGoodsAndNonemployeeServicesTransactionExpense	300000
CY2010	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	566000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1800000
CY2010	us-gaap	Operating Income Loss OperatingIncomeLoss	-44070000
CY2010	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3177000
CY2010	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1982000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19118000
CY2010	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43517000
CY2010	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	220000
CY2010	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2670000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2010	us-gaap	Equity Method Investment Summarized Financial Information Cost Of Sales EquityMethodInvestmentSummarizedFinancialInformationCostOfSales	24099000
CY2010	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4941000
CY2010	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	8601000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.016	pure
CY2010	us-gaap	Share Based Compensation ShareBasedCompensation	19118000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.013	pure
CY2010	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	413043000
CY2010	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	10494000
CY2010	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.04
CY2010	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	10669000
CY2010	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-9928000
CY2010	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.012	pure
CY2010	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-84341000
CY2010	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	-15498000
CY2010	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	17838000
CY2010	us-gaap	Investment Income Interest InvestmentIncomeInterest	2305000
CY2010	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-60705000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.042	pure
CY2010	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4732000
CY2010	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-62869000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.53	pure
CY2010	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37727000
CY2010	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2738000
CY2010	us-gaap	Restricted Stock Expense RestrictedStockExpense	2400000
CY2010	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1733000
CY2010	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-29000
CY2010	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-43001000
CY2010	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-52000
CY2010	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	390473000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.55	pure
CY2010	us-gaap	Operating Expenses OperatingExpenses	144111000
CY2010	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	-220000
CY2010	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	651000
CY2010	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	6400000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2010	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	15200000
CY2010	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-7639000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.367	pure
CY2010	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit
CY2010	us-gaap	Depreciation Depreciation	4800000
CY2010	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-5767000
CY2010	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.050	pure
CY2010	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19400000
CY2010	us-gaap	Gain Loss On Sale Of Previously Unissued Stock By Subsidiary Or Equity Investee Nonoperating Income GainLossOnSaleOfPreviouslyUnissuedStockBySubsidiaryOrEquityInvesteeNonoperatingIncome	4421000
CY2010	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	-15559000
CY2010	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42040000	shares
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.029	pure
CY2010	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9088000	shares
CY2010	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-52000
CY2010	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	993000
CY2010	us-gaap	Net Income Loss NetIncomeLoss	-43515000
CY2010	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1069000
CY2010	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	10742000
CY2010	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2594000
CY2010	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	2425000
CY2010	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	514000
CY2010	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-29000
CY2010	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	27000
CY2010	us-gaap	License And Services Revenue LicenseAndServicesRevenue	100041000
CY2010	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.98
CY2010	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-5516000
CY2010	alny	Equity Method Investment Summarized Financial Information Income Tax Expense Benefit EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxExpenseBenefit	-30000
CY2010	alny	Charge For Four Zero One K Company Stock Match ChargeForFourZeroOneKCompanyStockMatch	495000
CY2010	alny	Equity Method Investment Summarized Financial Information Other Income Expense EquityMethodInvestmentSummarizedFinancialInformationOtherIncomeExpense	91000
CY2010	alny	Non Cash Stock Based Compensation Expenses Research And Development NonCashStockBasedCompensationExpensesResearchAndDevelopment	11689000
CY2010	alny	Non Cash Stock Based Compensation Expenses General And Administrative NonCashStockBasedCompensationExpensesGeneralAndAdministrative	7429000
CY2010	alny	Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Value For Equity Method Investee AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValueForEquityMethodInvestee	289000
CY2011	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	52000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	40000
CY2011	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	376365000
CY2011	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.36
CY2011	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	300000
CY2011	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-10669000
CY2011	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	52000
CY2011	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-87068000
CY2011	us-gaap	Operating Income Loss OperatingIncomeLoss	-54818000
CY2011	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3512000
CY2011	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-531000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16676000
CY2011	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-58528000
CY2011	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	120000
CY2011	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	738000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2011	us-gaap	Equity Method Investment Summarized Financial Information Cost Of Sales EquityMethodInvestmentSummarizedFinancialInformationCostOfSales	20926000
CY2011	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5125000
CY2011	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	13789000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.012	pure
CY2011	us-gaap	Share Based Compensation ShareBasedCompensation	16676000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.002	pure
CY2011	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	-7137000
CY2011	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	81959000
CY2011	us-gaap	Investment Income Interest InvestmentIncomeInterest	1205000
CY2011	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-70255000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.046	pure
CY2011	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1291000
CY2011	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4371000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.55	pure
CY2011	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38280000
CY2011	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2731000
CY2011	us-gaap	Restricted Stock Expense RestrictedStockExpense	1500000
CY2011	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	103000
CY2011	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-57649000
CY2011	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	99295000
CY2011	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	738000
CY2011	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-52000
CY2011	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	293115000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.57	pure
CY2011	us-gaap	Operating Expenses OperatingExpenses	137575000
CY2011	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	-120000
CY2011	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	2457000
CY2011	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	6500000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2011	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	23000000
CY2011	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3505000
CY2011	us-gaap	Share Based Goods And Nonemployee Services Transaction Expense ShareBasedGoodsAndNonemployeeServicesTransactionExpense	400000
CY2011	us-gaap	Other Than Temporary Impairment Losses Investments Portion Recognized In Earnings Net OtherThanTemporaryImpairmentLossesInvestmentsPortionRecognizedInEarningsNet	595000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.361	pure
CY2011	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit
CY2011	us-gaap	Depreciation Depreciation	5000000
CY2011	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10657000
CY2011	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.033	pure
CY2011	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17100000
CY2011	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	-7602000
CY2011	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42410000	shares
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.026	pure
CY2011	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10091000	shares
CY2011	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-52000
CY2011	us-gaap	Net Income Loss NetIncomeLoss	-57649000
CY2011	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2831000
CY2011	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1982000
CY2011	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1023000
CY2011	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2011	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-879000
CY2011	us-gaap	License And Services Revenue LicenseAndServicesRevenue	82757000
CY2011	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.68
CY2011	alny	Equity Method Investment Summarized Financial Information Income Tax Expense Benefit EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxExpenseBenefit	206000
CY2011	alny	Charge For Four Zero One K Company Stock Match ChargeForFourZeroOneKCompanyStockMatch	488000
CY2011	alny	Equity Method Investment Summarized Financial Information Other Income Expense EquityMethodInvestmentSummarizedFinancialInformationOtherIncomeExpense	259000
CY2011	alny	Non Cash Stock Based Compensation Expenses Research And Development NonCashStockBasedCompensationExpensesResearchAndDevelopment	10921000
CY2011	alny	Non Cash Stock Based Compensation Expenses General And Administrative NonCashStockBasedCompensationExpensesGeneralAndAdministrative	5755000
CY2011	alny	Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Value For Equity Method Investee AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValueForEquityMethodInvestee	370000
CY2012	dei	Trading Symbol TradingSymbol	ALNY
CY2012	dei	Entity Registrant Name EntityRegistrantName	ALNYLAM PHARMACEUTICALS, INC.
CY2012	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012	dei	Amendment Flag AmendmentFlag	false
CY2012	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2012	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2012	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2012	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2012
CY2012	dei	Document Type DocumentType	10-K
CY2012	dei	Document Period End Date DocumentPeriodEndDate	2012-12-31
CY2012	dei	Entity Central Index Key EntityCentralIndexKey	0001178670
CY2012	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2012	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-10520000
CY2012	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Reclassifications</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Certain reclassifications have been made to prior years’ consolidated financial statements to conform to the 2012 presentation.</font></p> </div>
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4800000
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-129456000
CY2012	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1736000
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	86800000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2012	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	331000
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12360000
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-90187000
CY2012	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1441000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	18.47
CY2012	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6971000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2012	us-gaap	Equity Method Investment Summarized Financial Information Cost Of Sales EquityMethodInvestmentSummarizedFinancialInformationCostOfSales	17733000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9035000
CY2012	us-gaap	Equity Method Investment Summarized Financial Information Revenue EquityMethodInvestmentSummarizedFinancialInformationRevenue	9462000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.008	pure
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	12360000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	17.02
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.016	pure
CY2012	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.049	pure
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	162000
CY2012	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	289013000
CY2012	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-10572000
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.11
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	661909	shares
CY2012	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	128000
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	86800000
CY2012	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-1780000
CY2012	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Concentrations of Credit Risk and Significant Customers</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and fixed income marketable securities. At December 31, 2012 and 2011, substantially all of the Company’s cash, cash equivalents and fixed income marketable securities were invested in money market mutual funds, commercial paper, corporate notes and U.S. government securities through highly rated financial institutions. Investments are restricted, in accordance with the Company’s investment policy, to a concentration limit per issuer.</font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">To date, the Company’s revenues from collaborations have been generated from primarily F. Hoffmann-La Roche Ltd and certain of its affiliates (collectively, “Roche”) (which assigned its rights and obligations to Arrowhead Research Corporation (“Arrowhead”) in 2011), Takeda Pharmaceutical Company Limited (“Takeda”), and Novartis Pharma AG and one of its affiliates (collectively, “Novartis”). In addition, the Company and Medtronic, Inc. (“Medtronic”) formed a collaboration with CHDI Foundation, Inc. (“CHDI”) to advance ALN-HTT, a novel drug-device combination for the treatment of Huntington’s disease. Under this collaboration, CHDI agreed to initially fund approximately 50% of the costs of this program up to the point at which an investigational new drug application could be filed. In April 2012, the Company exercised its option under the Medtronic agreement to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT program and move to a royalty and milestone licensing structure. In connection with the Company’s opt-out, in May 2012, CHDI notified the Company and Medtronic that it would cease further funding of the ALN-HTT program pursuant to the terms of the CHDI agreement. The Company recorded the funding received from CHDI as a reduction to research and development expense. For the year ended December 31, 2012, the composition of the Company’s billed and unbilled collaboration receivables was entirely composed of amounts due from the U.S. Government for the wind-down of completed government contracts.</font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes customers that represent greater than 10% of the Company’s net revenues from research collaborators, for the periods indicated:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="81%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="10" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>Year Ended</b></font><br /> <font style="FONT-FAMILY: Times New Roman" size="1"><b>December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2010</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Roche/Arrowhead</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">56</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">68</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">56</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Takeda</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">33</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">27</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">22</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> </table> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The following table summarizes customers with amounts due that represent greater than 10% of the Company’s billed and unbilled collaboration receivables balance, at the periods indicated:</font></p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 6px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"> <tr> <td width="85%"></td> <td valign="bottom" width="7%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>At December 31,</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1">  </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2012</b></font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font size="1"> </font></td> <td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1"><b>2011</b></font></td> <td valign="bottom"><font size="1"> </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">U.S. Government</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">100</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2"></font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">CHDI</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">51</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr bgcolor="#CCEEFF"> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">GSK</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">20</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> <tr> <td valign="top"> <p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Medtronic</font></p> </td> <td valign="bottom"><font size="1">  </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">—</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td> <td valign="bottom"><font size="1"> </font></td> <td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td> <td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13</font></td> <td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td> </tr> </table> <p style="BORDER-BOTTOM: #000000 0.5pt solid; LINE-HEIGHT: 8px; MARGIN-TOP: 0px; WIDTH: 13%; MARGIN-BOTTOM: 2px">  </p> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 3px">  </p> <table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td valign="top" width="2%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"></font></td> <td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2">Represents 10% or less</font></td> </tr> </table> </div>
CY2012	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	52000
CY2012	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.091	pure
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-115609000
CY2012	us-gaap	Equity Method Investment Summarized Financial Information Income Loss From Continuing Operations Before Extraordinary Items EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems	-8271000
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3374000
CY2012	us-gaap	Investment Income Interest InvestmentIncomeInterest	977000
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-8562000
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.67
CY2012	us-gaap	Payments For Repurchase Of Common Stock For Employee Tax Withholding Obligations PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations	359000
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8348000
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-18823000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.57	pure
CY2012	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	44612000
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1780000
CY2012	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M6D
CY2012	us-gaap	Restricted Stock Expense RestrictedStockExpense	100000
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6402000
CY2012	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	255000
CY2012	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-116586000
CY2012	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="3%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>1.</b></font></td> <td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>NATURE OF BUSINESS</b></font></td> </tr> </table> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Alnylam Pharmaceuticals, Inc. (the “Company” or “Alnylam”) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference (“RNAi”). Alnylam is focused on discovering, developing and commercializing RNAi therapeutics by establishing strategic alliances with leading pharmaceutical and life sciences companies, establishing and maintaining a strong intellectual property position in the RNAi field, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics for its own account. The Company has devoted substantially all of its efforts to business planning, research and development, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital.</font></p> </div>
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	86569000
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	93412000
CY2012	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-52000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1418133	shares
CY2012	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	277129000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.00	pure
CY2012	us-gaap	Operating Expenses OperatingExpenses	196181000
CY2012	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2016-09-30
CY2012	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-3591000
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	6400000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350	pure
CY2012	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	38300000
CY2012	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4522000
CY2012	us-gaap	Share Based Goods And Nonemployee Services Transaction Expense ShareBasedGoodsAndNonemployeeServicesTransactionExpense	1000000
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.285	pure
CY2012	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-10572000
CY2012	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit
CY2012	us-gaap	Depreciation Depreciation	4600000
CY2012	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-17000
CY2012	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.007	pure
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12700000
CY2012	us-gaap	Gain Loss On Sale Of Previously Unissued Stock By Subsidiary Or Equity Investee Nonoperating Income GainLossOnSaleOfPreviouslyUnissuedStockBySubsidiaryOrEquityInvesteeNonoperatingIncome	16084000
CY2012	us-gaap	Equity Method Investment Summarized Financial Information Net Income Loss EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss	-10532000
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	50286000	shares
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-519000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.010	pure
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9536000	shares
CY2012	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-52000
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-106014000
CY2012	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12870000
CY2012	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1364000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1233086	shares
CY2012	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	879000
CY2012	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-10572000
CY2012	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i>Use of Estimates</i></b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</font></p> </div>
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15827000
CY2012	us-gaap	License And Services Revenue LicenseAndServicesRevenue	66725000
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.68
CY2012	alny	Lease Extension Period LeaseExtensionPeriod	P5Y
CY2012	alny	Lease Expiration Month And Year LeaseExpirationMonthAndYear	2016-09
CY2011Q1	us-gaap	Operating Expenses OperatingExpenses	36573000
CY2012	alny	Equity Method Investment Summarized Financial Information Income Tax Expense Benefit EquityMethodInvestmentSummarizedFinancialInformationIncomeTaxExpenseBenefit	-28000
CY2012	alny	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Percentage ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedPercentage	0.67	pure
CY2012	alny	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	3	Entity
CY2012	alny	Subleased Agreement Area SubleasedAgreementArea	34014	sqft
CY2012	alny	Operating Loss Carryforward Expiration Year OperatingLossCarryforwardExpirationYear	2032
CY2012	alny	Number Of Lease Extension Options NumberOfLeaseExtensionOptions	2	pure
CY2012	alny	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate	0.095	pure
CY2012	alny	Charge For Four Zero One K Company Stock Match ChargeForFourZeroOneKCompanyStockMatch	364000
CY2012	alny	Equity Method Investment Summarized Financial Information Other Income Expense EquityMethodInvestmentSummarizedFinancialInformationOtherIncomeExpense	2289000
CY2012	alny	Non Cash Stock Based Compensation Expenses Research And Development NonCashStockBasedCompensationExpensesResearchAndDevelopment	8041000
CY2012	alny	Non Cash Stock Based Compensation Expenses General And Administrative NonCashStockBasedCompensationExpensesGeneralAndAdministrative	4319000
CY2012	alny	Percentage Of Sharing In Development Cost PercentageOfSharingInDevelopmentCost	0.50	pure
CY2012	alny	Short Term Investment Maturity Period ShortTermInvestmentMaturityPeriod	90	D
CY2012	alny	Short Term Investment Maturity Period Minimum ShortTermInvestmentMaturityPeriodMinimum	P90D
CY2012	alny	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Percentage On First Anniversary ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPercentageOnFirstAnniversary	0.25	pure
CY2012	alny	Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationPeriod	P10Y
CY2012	alny	Adjustments To Additional Paid In Capital Share Based Compensation Requisite Service Period Recognition Value For Equity Method Investee AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValueForEquityMethodInvestee	321000
CY2012	alny	Cross License Restructuring Expense CrossLicenseRestructuringExpense	65000000
CY2012	alny	Other Comprehensive Income Unrealized Holding Gain Loss On Equity Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnEquitySecuritiesArisingDuringPeriodNetOfTax	15700000
CY2011Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2011Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42345000	shares
CY2011Q1	us-gaap	Net Income Loss NetIncomeLoss	-16285000
CY2011Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	20897000
CY2011Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2011Q2	us-gaap	Operating Expenses OperatingExpenses	33732000
CY2011Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42379000	shares
CY2011Q2	us-gaap	Net Income Loss NetIncomeLoss	-13824000
CY2011Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	20614000
CY2012Q1	us-gaap	Other Restructuring Costs OtherRestructuringCosts	3900000
CY2012Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2012Q1	us-gaap	Operating Expenses OperatingExpenses	31480000
CY2012Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46210000	shares
CY2012Q1	us-gaap	Net Income Loss NetIncomeLoss	-11368000
CY2012Q1	us-gaap	License And Services Revenue LicenseAndServicesRevenue	20587000
CY2012Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2012Q2	us-gaap	Operating Expenses OperatingExpenses	32951000
CY2012Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	51280000	shares
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-12956000
CY2012Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	20884000
CY2011Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2011Q3	us-gaap	Operating Expenses OperatingExpenses	33229000
CY2011Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42654000	shares
CY2011Q3	us-gaap	Net Income Loss NetIncomeLoss	-13237000
CY2011Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	20791000
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.38
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	34906000
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	51542000	shares
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-19502000
CY2012Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	16759000
CY2011Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2011Q4	us-gaap	Operating Expenses OperatingExpenses	34041000
CY2011Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42715000	shares
CY2011Q4	us-gaap	Net Income Loss NetIncomeLoss	-14303000
CY2011Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	20455000
CY2012Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.20
CY2012Q4	us-gaap	Operating Expenses OperatingExpenses	96844000
CY2012Q4	us-gaap	Income Tax Expense Benefit Intraperiod Tax Allocation IncomeTaxExpenseBenefitIntraperiodTaxAllocation	-10572000
CY2012Q4	us-gaap	Gain Loss On Sale Of Previously Unissued Stock By Subsidiary Or Equity Investee Nonoperating Income GainLossOnSaleOfPreviouslyUnissuedStockBySubsidiaryOrEquityInvesteeNonoperatingIncome	16084000
CY2012Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	51821000	shares
CY2012Q4	us-gaap	Net Income Loss NetIncomeLoss	-62188000
CY2012Q4	us-gaap	License And Services Revenue LicenseAndServicesRevenue	8495000
CY2012Q4	alny	Equity Investments Other Than Equity Method Ownership Percentage EquityInvestmentsOtherThanEquityMethodOwnershipPercentage	0.17	pure
CY2012Q4	alny	Cross License Restructuring Expense CrossLicenseRestructuringExpense	65000000

Files In Submission

Name	View Source	Status
0001193125-13-065475-index-headers.html	Edgar Link	pending
0001193125-13-065475-index.html	Edgar Link	pending
0001193125-13-065475.txt	Edgar Link	pending
0001193125-13-065475-xbrl.zip	Edgar Link	pending
alny-20121231.xml	Edgar Link	completed
alny-20121231.xsd	Edgar Link	pending
alny-20121231_cal.xml	Edgar Link	unprocessable
alny-20121231_def.xml	Edgar Link	unprocessable
alny-20121231_lab.xml	Edgar Link	unprocessable
alny-20121231_pre.xml	Edgar Link	unprocessable
d440212d10k.htm	Edgar Link	pending
d440212dex1016.htm	Edgar Link	pending
d440212dex1049.htm	Edgar Link	pending
d440212dex1050.htm	Edgar Link	pending
d440212dex1051.htm	Edgar Link	pending
d440212dex1052.htm	Edgar Link	pending
d440212dex12.htm	Edgar Link	pending
d440212dex211.htm	Edgar Link	pending
d440212dex231.htm	Edgar Link	pending
d440212dex232.htm	Edgar Link	pending
d440212dex311.htm	Edgar Link	pending
d440212dex312.htm	Edgar Link	pending
d440212dex321.htm	Edgar Link	pending
d440212dex322.htm	Edgar Link	pending
d440212dex991.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
g440212ex10_49pg102.jpg	Edgar Link	pending
g440212ex10_49pg104.jpg	Edgar Link	pending
g440212ex10_49pg112.jpg	Edgar Link	pending
g440212ex10_49pg85a.jpg	Edgar Link	pending
g440212ex10_49pg85b.jpg	Edgar Link	pending
g440212ex10_49pg86a.jpg	Edgar Link	pending
g440212ex10_49pg86b.jpg	Edgar Link	pending
g440212ex10_51pg36.jpg	Edgar Link	pending
g440212ex10_51pg40.jpg	Edgar Link	pending
g440212g27x98.jpg	Edgar Link	pending
g440212g44e82.jpg	Edgar Link	pending
g440212g58e17.jpg	Edgar Link	pending
g440212xbrl_exhibit10-161.jpg	Edgar Link	pending
g440212xbrl_exhibit10-167.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2013 Q1 Form 10-K Financial Statement

#000119312513065475 Filed on February 19, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY ALNYLAM PHARMACEUTICALS, INC. Stock $alny

2013 Q1 Form 10-K Financial Statement

#000119312513065475 Filed on February 19, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALNY
ALNYLAM PHARMACEUTICALS, INC. Stock $alny